Evidence map›Paper›PMID 36107307›Full record

ArticlePharmacoEconomics - open2022

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif, Nicholas Adlard, Philip Cooney, François Blanchette, Barkha P Patel, Daniel Grima

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PharmacoEconomics - open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Moogeh Baharnoori *Department of Medicine, Queen's University, Kingston, ON, Canada.
Virender Bhan *Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.
Fraser Clift *Department of Neurology, Memorial University of Newfoundland, St. John's, NL, Canada.
Kimberly ThomasEVERSANA, Burlington, ON, Canada.
Soukaïna MouallifNovartis Canada Inc., 385, boulevard Bouchard, Dorval, QC, H9S 1A9, Canada. soukaina.mouallif@novartis.com.
Nicholas AdlardNovartis Pharma AG, Basel, Switzerland.
Philip CooneyNovartis Ireland Limited, Dublin, Ireland.
François BlanchetteNovartis Canada Inc., 385, boulevard Bouchard, Dorval, QC, H9S 1A9, Canada.
Barkha P PatelEVERSANA, Burlington, ON, Canada.
Daniel GrimaEVERSANA, Burlington, ON, Canada.
EVERSANA (Canada) · CANovartis (Canada) · CAMemorial University of Newfoundland · CANovartis (Ireland) · IENovartis (Switzerland) · CHQueen's University · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOfatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada.

objectiveThe aim of this study was to evaluate the cost effectiveness of ofatumumab from a Canadian healthcare system perspective.

methodsA Markov cohort model was run over 65 years using annual cycles, 1.5% annual discount rate, and 100% treatment discontinuation at 10 years. The British Columbia database informed natural history transition probabilities. Treatment efficacy for DMTs were sourced from a network meta-analysis. Clinical trial data were used to estimate probabilities for treatment-related adverse events. Health utilities and costs were obtained from Canadian sources (if available) and the literature.

resultsAmong first-line indicated therapies for RRMS, ofatumumab was dominant (more effective, lower costs) over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab. Compared with glatiramer acetate and best supportive care, ofatumumab resulted in incremental cost-effectiveness ratios (ICERs) of $24,189 Canadian dollars per quality-adjusted life-year (QALY) and $28,014/QALY, respectively. At a willingness-to-pay threshold of $50,000/QALY, ofatumumab had a 64.3% probability of being cost effective. Among second-line therapies (scenario analysis), ofatumumab dominated natalizumab and fingolimod and resulted in an ICER of $50,969 versus cladribine.

conclusionsOfatumumab is cost effective against all comparators and dominant against all currently approved and reimbursed first-line DMTs for RRMS, except glatiramer acetate.

Identifiers

PMID36107307
PMCPMC9596641
OpenAlexW4295905156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.